Bridgeway Capital Management’s Metagenomi Therapeutics MGX Stock Holding History

Bridgeway Capital Management’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$530K	Hold	395,800	–	–	0.01%	818
2025 Q4	$641K	Buy	395,800 +200,000	+102%	+$433K	0.01%	778
2025 Q3	$464K	Buy	195,800 +97,100	+98%	+$197K	0.01%	819
2025 Q2	$146K	Hold	98,700	–	–	﹤0.01%	1017
2025 Q1	$134K	Buy	98,700 +6,500	+7%	+$15.5K	﹤0.01%	992
2024 Q4	$333K	Hold	92,200	–	–	0.01%	899
2024 Q3	$200K	Buy	+92,200	New	+$320K	﹤0.01%	1067

Other funds holding MGX

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bridgeway Capital Management's MGX Position: Q1 2026 in Review

Bridgeway Capital Management held its Metagenomi Therapeutics (MGX) position steady in Q1 2026 at 395,800 shares worth $530K. The position accounts for 0.01% of the portfolio, ranked #818.

Bridgeway Capital Management first reported a position in MGX in Q3 2024 and has held it in 7 quarters since. The position peaked at $641K in Q4 2025. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

Bridgeway Capital Management held 395,800 shares of Metagenomi Therapeutics worth $530K as of Q1 2026.
Bridgeway Capital Management left its Metagenomi Therapeutics share count unchanged in Q1 2026.
Metagenomi Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #818 holding.
Bridgeway Capital Management first reported a position in Metagenomi Therapeutics in Q3 2024 and has held it in 7 quarters since.
Bridgeway Capital Management's Metagenomi Therapeutics position peaked at $641K in Q4 2025.
48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.